Viewing Study NCT05026866


Ignite Creation Date: 2025-12-24 @ 4:02 PM
Ignite Modification Date: 2025-12-26 @ 11:48 PM
Study NCT ID: NCT05026866
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-17
First Post: 2021-08-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Sponsor: Eli Lilly and Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module